EMA Authorised: Exjade (deferasirox) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Exjade (deferasirox) by Novartis Europharm Limited for beta-thalassemia and iron overload in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Iron Overload

Drugs mentioned

• Exjade (deferasirox)

Snippet

Status: Authorised. Therapeutic area: beta-Thalassemia;Iron Overload. MAH: Novartis Europharm Limited. Decision date: 04/02/2026